

Pathway analysis


Biostat & Bioinfo short course series
02/08/2019
Jianying Li

An outline of the pathway analysis course

- Background of pathway analysis
- Random variable distribution and its usage in the pathway analysis
- A parametric approach
 - Hypergeometric distribution in details
 - An example: IPA
- Non-parametric approach
 - Experimental layout
 - An example: GSEA
- Pathway analysis summary
 - Making a right choice
 - Pros and cons
- Hands on practice
 - R and basic distribution
 - GSEA



The Road to Pathway Analysis



Why pathway analysis?


- Biological responses are systematic and collaborative
- Modern technologies provide high-throughput measurement
- Rich knowledge-based accumulation available
- Statistical frame works provide the analytical component

Common experimental rationale

- An established measurement of gene expression profile:
 - Microarray
 - RNAseq
 - Nano-string
 - Etc.
- Samples obtained from two conditions (e.g. treated vs. control)
- Several biological replicates at each condition
- Our focus is "how would a study object respond differently at two conditions?)
- Gene-centered analysis often
 - Asses statistical difference between conditions via some testing, t-test, limma etc.
 - Correct for multiple testing issues
 - Obtain a set of differentially expressed genes (DEGs)
- Where is the biology??

The oxidative phosphorylation

 A set of molecules in a cell that work together through a series of actions to achieve a particular outcome



http://employees.csbsju.edu/hjakubowski/classes/ch331/oxphos/olcouplingoxphos.html

Rich knowledge-based accumulation available

- GeneOntology (originated since 1998)
 - Molecular function describing activities, such as catalytic or binding activities, at the molecular level
 - Biological process referring to a biological objective to which the gene product contributes
 - Cellular component referring to the place in the cell (i.e. the location) where a gene product is found
- KEGG pathway (originated since 1996)
 - Metabolism: carbohydrates, energy, lipid, nucleotides, amino acid, xenobiotics
 - Human diseases
 - Genetic information processing
- Transfac/Transpath
 - Data on transcription factors, their experimentally-proven binding sites, and regulated genes
 - Protein-protein interactions and directed modification of proteins involved in signal transduction pathways,
- It is a knowledge based/driven approach
- Pathway --- gene sets are interexchange

Gene sets – generalized definition

Gene sets are sets of genes that have something in common, e.g., that they are

- > part of the same pathway
- coding for proteins that are part of the same cellular component
- > co-expressed under certain conditions
- > putative targets of the same regulatory factor
- > on the same cytogenetic band
- have come up as hits in some published assay
- Etc.

Molecular Signatures Database (MSigDB v5.2)

Free database (http://www.broadinstitute.org/gsea/msigdb)

hallmark gene sets are coherently expressed signatures derived by aggregating many MSigDB gene sets to represent well-defined biological states or processes.

C1 positional gene sets for each human chromosome and cytogenetic band.

curated gene sets from online pathway databases, publications in PubMed, and knowledge of domain experts.

motif gene sets based on conserved cis-regulatory motifs from a comparative analysis of the human, mouse, rat, and dog genomes.

C4 computational gene sets defined by mining large collections of cancer-oriented microarray data.

C5 GO gene sets consist of genes annotated by the same GO terms.

oncogenic signatures defined directly from microarray gene expression data from cancer gene perturbations.

immunologic signatures defined directly from microarray gene expression data from immunologic studies.





Transcription Pathways Ontologies Disease/Drugs Cell Types Legacy Crowd Misc Description overlap between up genes of Gene-set Example and dn genes of CGP-60474 (12 genes) ChEA 2016 TRANSFAC and JASPAR Genome Browser PWMs **PWMs** STAT3_1855785_ChIP-Seq_MESCs_Mouse Zfx (mouse) V\$IK1_01 KCTHETA_26484144_Chip-Seq_BREAST_Hun V\$NFKAPPAB_01 ARNT (human) LOCK_20551151_ChIP-Seq_293T_Human /\$BACH2_01 P4 (human) F7 22180533 ChIP-Seq_HELA_Human A 27197147 Chip-Seq ENDOMETRIOID-A **ENCODE and ChEA** Epigenomics Roadmap HM TargetScan microRNA ChIP-seq Consensus TFs from ChIP-X H2BK120ac H9 CTTTGCA,MIR-527 RELA_ENCODE H3K27ac Brain Cingulate Gyrus GTTAAAG,MIR-302B H3K27me3 iPS DF 19.11 H3K4me2 IMR90 ACTGTG,MIR-128A,MIR-128B H3K4me2 H9 **ENCODE TF ChIP-seq 2015** TF-LOF Expression from **ENCODE Histone** Modifications 2015 GEO stat3_00000000_a549_lof_human_gpl571_gs H3K4me3_GM12864_hg19 POLR2A_bone marrow macrophage_mm9 ezh2_22267199_heart_lof_mouse_gpl6246_g RELA_GM18526_hg19 H3K27ac_osteoblast_hg19 ATA2_endothelial cell of umbilical vein_hg1 mx2_20962046_e10dot5_urogenital_epithe 3K27ac_fibrob ast of dermis_hg19 ELA_GM12891_hg19 nt1_15448691_hela_lof_human_gpl8300_g A3_SK-N-SH_hg19 ka1_21151129_mcfdash7_lof_human_gpl1i letal muscle myoblast_hg19 **Transcription Factor PPIs** PPARG

http://amp.pharm.mssm.edu/Enrichr/enrich

The statistical framework

- Well-established statistical and computation algorithms
- Parametric method
 - Hypergeometric test
 - Fisher's exact test
- Non-parametric approaches
 - GSEA
 - GSA
 - Etc.
- Other algorithms
 - Auto expand: Draws sub-networks around the selected objects
 - Shortest paths: Uses Dijkstra's shortest paths algorithm to find the shortest directed paths between the selected objects.
 - Self regulation: Finds the shortest directed paths containing transcription factors between the selected objects
 - Etc.

A good place to start

- A simple example:
 - 5 patients with the disease D and 5 healthy control subjects
 - Checked for elevated levels of the blood constituent C.
 - 4 of the patients, but only 2 of the healthy subjects show an elevated level of *C*.
- May we infer that the concentration of C is elevated inpatients with disease D more often than in healthy subjects?
- Or could our result have been mere coincidence?

2x2 contingency table

| | Patient with disease D | Healthy control subject | Total |
|------------------------------|------------------------|-------------------------|-------|
| Elevated level of compound C | 4 | 2 | 6 |
| Normal level of compound C | 1 | 3 | 4 |
| Total | 5 | 5 | 10 |

$$E_{r,c} = \frac{(\text{Sum of row } r) \times (\text{Sum of column } c)}{\text{Sample size}}$$

| | Patient with disease D | Healthy control subject | Total |
|------------------------------|------------------------|-------------------------|-------|
| Elevated level of compound C | 4 (3) | 2 (3) | 6 |
| Normal level of compound C | 1 (2) | 3 (2) | 4 |
| Total | 5 | 5 | 10 |

Probability to get this 2×2 table without an association between *D* and *C*:

```
Number of ways to Number of ways to
choose 4 out of 5 \times choose 2 out of 5
    patiens to
                            controls to
 \frac{\text{have elevated C}}{\text{nuber of ways to}} = \frac{4}{10}
            choose 6 our of 10
             persons to have
                 elevated C
                   in R:
                   > dhyper(4, 5, 5, 6)
                   [1] 0.2380952
```



Under the null hypothesis, i.e., the assumption that there is no association between elevated levels of compound *C* and presence of disease *D*, the probability that all 5 patients have elevated levels of C would be,

| | Patient with disease D | Healthy control subject | Total |
|------------------------------|------------------------|-------------------------|-------|
| Elevated level of compound C | 5 | 1 | 6 |
| Normal level of compound C | 0 | 4 | 4 |
| Total | 5 | 5 | 10 |

in R: > dhyper(5, 5, 5, 6) [1] 0.02380952


Under the null hypothesis, i.e., the assumption that there is no association between elevated levels of compound *C* and presence of disease *D*, the probability that 4 or even more of the patients have elevated levels of C,

$$p = \frac{\binom{5}{4}\binom{5}{2}}{\binom{10}{6}} + \frac{\binom{5}{5}\binom{5}{2}}{\binom{10}{6}} = 0.26$$

This is insignificant

```
in R: > 1 - phyper(3, 5, 5, 6) [1] 0.2619048
```

Hypergeometric Test (Right-tailed)




- An urn with two types of marbles:
 - N total # of marbles
 - Of which, m # of red marbles
 - Drawing a red marble is a success!
 - Drawing a white marble is a failure!
- n is the # of marbles randomly drawn
- k is the # of successes (red marbles) in the sample
- Hypergeometric distribution gives the probability


$$P(X = k) = \frac{\binom{m}{k} \binom{N-m}{n-k}}{\binom{N}{n}}. \quad \text{for } k = 0, 1, 2, ..., n \\ k < = m, n-k < = N-m$$

- Number of red ball: 50
 Number of white ball: 120
- Number of ball drawn (without replacement): 36 ← n
- Possible number of success ??
 - (0,1, 2,36),
- Probability to get $\frac{20}{10}$ red balls is: 0.0001494571 p(k=20, 36, 50, 170)

Probablity getting # of success!



Pathway analysis (behind the scene)



So, now you are probably given something like the following:

```
x <- 5 #num_of_DEG in GO

m <- 20 #num_of_gene on chip in GO

n <- 500 #num_of_gene on chip NOT in GO

k <- 40 #num_of_DEG
```

Hypergeometric test vs. FET, we shall get same result

- phyper((x-1), m, n, k, lower.tail=FALSE)
- (fisher.test(matrix(c(x,(k-x), (m-x), (n-k+x)),2,2), alternative='greater'))\$p.value

Quick Start

INGENUITY **PATHWAY ANALYSIS**

Start Here

Learning IPA

Shortcuts

×

Explore



Datasets

Annotate and filter datasets and use them directly for hypothesis generation when exploring pathways and gene lists.

> Annotate Datasets

> Filter datasets



Core

Analyze

Interpret your data in the context of biological processes, pathways, and networks.

> Analyze dataset

> Compare analyses





Identify the union, unique, and common molecules across lists, pathways, biomarkers, and analyses.

> Compare data



IPA-Tox

Assess toxicity and safety of test compounds in the context of toxicological processes, pathways, and networks.

> Analyze dataset

> Compare analyses



Pathways

Create pathways from your datasets, targets, biomarkers, diseases and biological functions. Communicate pathways and network results through visually enhanced representations.

> Build pathways > Design pathways



IPA-Biomarker

Filter your datasets and identify and prioritize potential biomarker candidates.

> Analyze dataset

> Compare analyses



IPA-Metabolomics

Explore genotype-phenotype relationships and environmental influences via metabolite data.

> Analyze dataset

> Compare analyses

Ingenuity Pathway Analysis (IPA)


--Knowledgebase

- Desktop Java application utilizing a remote server for data, analysis and file management
- IPA Ontology: Curation of the scientific literature and content extraction of the IPA repository of molecular interactions, regulatory events, biological processes, gene-to-phenotype associations, and chemical knowledge

| Ingenuity® Expert Findings | Experimentally demonstrated Findings that are manually curated for accuracy and contextual details from the full-text of articles in top journals. |
|----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| Ingenuity® ExpertAssist Findings | Manually reviewed, automatically extracted Findings from the abstracts of a broad range of recently published journal articles. |
| Ingenuity® Expert Knowledge | Knowledge modeled by Ingenuity experts such as pathways, toxicity lists, and more. |
| Ingenuity® Supported Third Party Information | Manually reviewed content from selected sources and databases such as BIND, Argonaute 2, etc. |

IPA Enrichment Analysis

- Uses the Fisher's exact test to determine the significance of a functional group or pathway
 - # molecules in a list that are associated with a function/pathway (k)
 - total # of molecules that are associated with a function/pathway (m)
 - # of molecules in all possible functions/pathways (N)
 - # of molecules in a list (n)



All the DEGs in the pathway are up-regulated

Hypergeometric Test (Right-tailed)

- Used in Ingenuity Pathway Analysis (IPA)
 - Commercial software (http://www.ingenuity.com/products/ipa)
 - Pros:
 - Great source of clean, expertly curated gene sets
 - Cons:
 - Not free
 - Throws away information by only using DEG list

Hypergeometric Test (Right-tailed)

- Used in Database for Annotation, Visualization and Integrated Discovery (DAVID)
 - Free software (https://david.ncifcrf.gov)
 - Pros:
 - Easy to use (web-based)
 - Large collection of gene sets
 - Cons:
 - Gene sets are not as clean
 - Throws away information by only using DEG list

Sampling over genes

- Hypergeometric testing for gene sets has been criticized on the ground of it sampling over genes (observation) instead of over microarrays (subjects)
- Hence, the meaning of the p values is quite unclear.
- Especially: Correlations between genes inflate the apparent sample size, causing potentially severe over-estimation of significance.
- Increasing the number of replicates influences significance only indirectly.

Sampling over subjects

- Instead of using the hypergeometric distribution to get a p value from out statistic, we should better use subject permutation:
 - Let L_0 be the list of differential expressed genes and $m=|L_0|$ its size.
 - For **N** permutations σ_i (i=1,...,N) of the subject labels, calculate the DE statistic and let Li be the list of the m top ranking genes.
 - Let k_i be the number of differentially expressed genes in the gene set, i.e. the size of the intersection $L_i \cap S$.
 - The p value for gene set S is now the fraction of permutation that had a larger gene set than the correct sample assignment, i.e.,

$$p = \frac{|\{i | k_i > k_0\}|}{N}$$

The universe matters

It is important to choose the universe correctly

Case 1: universe is all genes in the genome

| | DEGs | Non-DEGs | Total |
|-----------|------|----------|-------|
| In GO | 10 | 30 | 40 |
| Not in GO | 390 | 3570 | 3960 |
| Total | 400 | 3600 | 4000 |


p=0.049

Case 2: universe is only expressed genes

| | DEGs | Non-DEGs | Total |
|-----------|------|----------|-------|
| In GO | 10 | 30 | 40 |
| Not in GO | 390 | 570 | 960 |
| Total | 400 | 600 | 1000 |

p=0.0048


Sets are overlapped



Set B is enriched only because of it overlap with set A



The subgraph induced by the 10 most significant GO terms identified by a current state-ofthe-art method for scoring GO terms for enrichment.



Alexa A et al. Bioinformatics 2006;22:1600-1607

☐ TopGO's elimination algorithm

Test the leaf sets first. If significant, remove its "genes" before testing its ancestor sets

TopGO's weight algorithm

The genes are weighted by their relevance in the significant nodes.

- The enrichment score of a parent (gene node u) is compared with the scores of its children.
- Children with a better score than u represent the interesting genes better.

 Therefore, their significance is increased Children with a lower score than u have their significance reduced.



A non-parametric approach

- Compare a sample empirical distribution function to the reference distribution
- Or, compare two sample empirical distribution functions
- Required data:
 - Ranked list of genes sorted by differential expression (includes all genes)
 - A gene set
- If the genes in the gene set tend to fall near either end of the ranked list, the gene set is considered significantly enriched
- The test significance is obtained from empirical distribution
 - Permutation based
 - Bootstrapping
 - Etc.

A non-parametric approach (GSEA)


- Mootha et al. [2003] suggest to use Kolmogorov-Smirnov (K-S) test
 - Sort all genes by LFC.
 - Go through the list, increasing a running sum for each gene in the gene set by (N-n), and decreasing it for each gene not in the gene set by n.
 - [N: number of genes, n: size of gene set]
 - The maximum value of the running sum is the enrichment score (ES).

A non-parametric approach

- Assessing significance
 - To get p values, we do not use the KS distribution but rather estimate the null by subject permutation
- Improved enrichment score
 - The KS statistic tests whether distributions are different, but this difference may not have a clear direction, making biological interpretation difficult
 - The updated GSEA algorithm [Subramanian et al., PNAS 102 (2005) 15545] weights the in-/decrements of the running sum by the LFC.




A GSEA overview illustrating the method.





Subramanian A et al. PNAS 2005;102:15545-15550


Kolmogorov–Smirnov (KS) Test




Kolmogorov–Smirnov (KS) Test









(upregulated) Gene Set (downregulated)




(upregulated) Gene Set (downregulated)











Maximum deviation from zero provides the enrichment score *ES(S)*





Mootha et al., Nature Genetics, 2003, 34(3):267-273

- Used in Gene Set Enrichment Analysis (GSEA)
 - Free software (http://www.broadinstitute.org/gsea)
 - Pros:
 - Large collection of gene sets
 - Uses more information than methods that only use DEG list
 - Enrichment plot improves interpretability
 - Cons:
 - Permutation-based p-values

Hands on practice on both parametric and non-parametric

NOW, IT IS YOUR TURN

Click to download



GSEA Home

Downloads

Molecular Signatures Database

Documentation

Contact

Overview

Gene Set Enrichment Analysis (GSEA) is a computational method that determines whether an a priori defined set of genes shows statistically significant, concordant differences between two biological states (e.g. phenotypes).


From this web site, you can:

- Download the GSEA software and additional resources to analyze, annotate and interpret enrichment results.
- Explore the Molecular Signatures Database (MSigDB), a collection of annotated gene sets for use with GSEA software.
- View documentation describing GSEA and MSigDB.

What's New

05-Jun-2013: Version 4.0 of the Molecular Signatures Database (MSigDB) is now available, which includes a new gene set collection (C7) of 1,910 immunologic signatures generated as part of the Human Immunology Project Consortium. We also released a newer version (2.0.13) of the GSEA desktop application. There were no changes to the GSEA algorithm.

29-May-2013: GSEA and MSigDB may experience intermittent connectivity issues on Monday, June 3rd between the hours of 6AM and 9AM (Eastern



Registration

Please register to download the GSEA software and view the MSigDB gene sets. After registering, you can log in at any time using your email address. Registration is free. Its only purpose is to help us track usage for reports to our funding agencies.

Contributors



GSEA Home

Downloads

Molecular Signatures Database

Documentation

Contact

Login to GSEA/MSigDB

Login

Click here to register to view the MSigDB gene sets and/or download the GSEA software. This helps us track and better serve our user community.

If you have already registered for GSEA or MSigDB please enter your registration email address below.

Items marked with * are required.






Downloads


The GSEA software and source code and the Molecular Signatures Database (MSigDB) are freely available to individuals in both academia and industry for internal research purposes. Please see the GSEA/MSigDB license for more details.


Software

There are several options for GSEA software. All options implement exactly the same algorithm. Usage recommendations and installation instructions are listed below. Current Java implementations of GSEA require Java 6 or 7.


| javaGSEA Desktop Application | Easy-to-use graphical user interface Runs on any desktop computer (Windows, Mac OS X, Linux etc.) that supports Java 6 or 7 Produces richly annotated reports of enrichment results Integrated gene sets browser to view gene set annotations, search for gene sets and managene sets between platforms | Launch with 1GB (for 32 or 64-bit Java) memory: Launch |
|-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|
| javaGSEA Java Jar file | Command line usage Runs on any platform that supports Java 6 or 7 We recommend using the 'Launch' buttons above instead of this mode for most users | download gsea2-2.2.0.jar |
| R-GSFA | ► Usage from within the R programming environment | download |










- Supported file types:
 - http://www.broadinstitute.org/cancer/software/gsea/wiki/index.php/
 Data formats
- Required:
 - Expression data file
 - Class label file
- Optional:
 - Gene set file









Enrichment in phenotype: Male (12 samples)

- · 31 / 378 gene sets are upregulated in phenotype Male
- 0 gene sets are significant at FDR < 25%
- 0 gene sets are significantly enriched at nominal pvalue < 1%
- 1 gene sets are significantly enriched at nominal pvalue < 5%
 Snapshot of enrichment results
- Detailed enrichment results in html format
- Detailed enrichment results in excel format (tab delimited text)
- Guide to interpret results

Enrichment in phenotype: Female (12 samples)

- · 347 / 378 gene sets are upregulated in phenotype Female
- 4 gene sets are significantly enriched at FDR < 25%
- 4 gene sets are significantly enriched at nominal pvalue < 1%
- 5 gene sets are significantly enriched at nominal pvalue < 5%
- Snapshot of enrichment results
 Detailed enrichment results in html format
- Detailed enrichment results in excel format (tab delimited text)
- Detailed enrichment results in excel format (tab delimited text)
 Guide to interpret results

Dataset details

- · The dataset has 3750 native features
- After collapsing features into gene symbols, there are: 2736 genes

Gene set details


- Gene set size filters (min=15, max=500) resulted in filtering out 1076 / 1454 gene sets
- The remaining 378 gene sets were used in the analysis
- List of gene sets used and their sizes (restricted to features in the specified dataset)

Gene markers for the Male versus Female comparison


- · The dataset has 2736 features (genes)
- # of markers for phenotype Male: 310 (11.3%) with correlation area 10.8%
- # of markers for phenotype Female: 2426 (88.7%) with correlation area 89.2%
- . Detailed rank ordered gene list for all features in the dataset
- Heat map and gene list correlation profile for all features in the dataset
- <u>Buttefly plot</u> of significant genes


| | GS follow link to MSigDB | GS DETAILS | SIZE | ES | NES | NOM p-val | FDR q-val | FWER p-val | RANK AT MAX | LEADING EDGE |
|----|------------------------------------------------|---------------|------|-------|-------|--------------|--------------|------------|----------------|--------------------------------------|
| 1 | STEROID_METABOLIC_PROCESS | Details | 1 | -0.59 | -1.86 | 0.000 | 0.247 | 0.093 | 326 | tags=35%, list=12%, signal=40% |
| 2 | MONOCARBOXYLIC_ACID_METABOLIC_PROCESS | Details | 27 | -0.47 | -1.84 | 0.004 | 0.146 | 0.107 | 644 | tags=37%, list=24%, signal=48% |
| 3 | CELLULAR_LIPID_METABOLIC_PROCESS | Details | 64 | -0.45 | -1.81 | 0.000 | 0.136 | 0.138 | 575 | tags=31%, list=21%, signal=39% |
| 4 | FATTY_ACID_METABOLIC_PROCESS | Details | 19 | -0.59 | -1.76 | 0.008 | 0.184 | 0.217 | 644 | tags=47%, list=24%, signal=62% |
| 5 | LIPID_METABOLIC_PROCESS | Details | 78 | -0.39 | -1.65 | 0.014 | 0.410 | 0.415 | 675 | tags=29%, list=25%, signal=38% |
| 6 | CARBOXYLIC_ACID_METABOLIC_PROCESS | Details | 51 | -0.32 | -1.45 | 0.090 | 1.000 | 0.696 | 696 | tags=24%, list=25%, signal=31% |
| 7 | ORGANIC_ACID_METABOLIC_PROCESS | Details | 51 | -0.32 | -1.45 | 0.090 | 1.000 | 0.696 | 696 | tags=24%, list=25%, signal=31% |
| 8 | LIPID_BIOSYNTHETIC_PROCESS | Details | 22 | -0.46 | -1.40 | 0.150 | 1.000 | 0.747 | 575 | tags=36%, list=21%, signal=46% |
| 9 | GOLGI_APPARATUS | Details | 30 | -0.43 | -1.39 | 0.076 | 1.000 | 0.753 | 379 | tags=37%, list=14%, signal=42% |
| 10 | GTPASE_ACTIVITY | Details | 15 | -0.50 | -1.38 | 0.092 | 1.000 | 0.761 | 195 | tags=33%, list=7%, signal=36% |
| 11 | CELL_MIGRATION | Details | 22 | -0.48 | -1.35 | 0.121 | 1.000 | 0.781 | 969 | tags=64%, list=35%, signal=98% |
| 12 | OXIDOREDUCTASE_ACTIVITY | Details | 66 | -0.27 | -1.34 | 0.119 | 1.000 | 0.783 | 284 | tags=12%, list=10%, signal=13% |
| 13 | TRANSMEMBRANE_RECEPTOR_PROTEIN_KINASE_ACTIVITY | Details | 15 | -0.53 | -1.34 | 0.105 | 1.000 | 0.794 | 795 | tags=67%, list=29%, signal=93% |
| | | | | | | | | | | |

| Table: GSEA Results Summary | | |
|-----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| Dataset | DEG_overall_gender_diff_overall_gender_diff_collapsed_to_symbols.gender_label_word.cls #Male_versus_Female_gender_label_word.cls #Male_versus_Female_repos | |
| Phenotype | gender_label_word.cls#Male_versus_Female_repos | |
| Upregulated in class | Female | |
| GeneSet | STEROID_METABOLIC_PROCESS | |
| Enrichment Score (ES) | -0.5875557 | |
| Normalized Enrichment Score (NES) | -1.8563647 | |
| Nominal p-value | 0.0 | |
| FDR q-value | 0.24662763 | |
| FWER p-Value | 0.093 | |



Lipid metabolism enriched -- GSEA





- http://www-stat.stanford.edu/~tibs/GSA/
- http://www.netsci.org/Resources/Software/Bioinform/pathwayan alysis.html
- http://www.broadinstitute.org/gsea/index.jsp
- http://david.abcc.ncifcrf.gov/
- http://www.biocarta.com/
- http://web.expasy.org/pathways/
- http://www.genmapp.org/
- http://www.genome.jp/kegg/
- http://www.ingenuity.com/
- http://www.genego.com/metacore.php
- http://www.geneontology.org/
- http://omicslab.genetics.ac.cn/GOEAST/tutorial.php
- http://expressome.kobic.re.kr/GAzer/document.jsp
- <u>http://www.biobase-international.com/products</u>
- http://jaspar.genereg.net/